BQ-123
Also known as: BQ 123, BQ‑123, Cyclo(-Asp-Pro-Phe-Leu-Leu-Arg-), cyclo(D-Asp-Pro-D-Val-Leu-D-Trp), Endothelin-A receptor antagonist BQ-123
Source BQ-123 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
BQ‑123 is a cyclic hexapeptide that selectively blocks ET_A receptors and is widely used in pre‑clinical studies to explore endothelin‑mediated pathways.
Mechanism of Action
Competitive antagonism of the endothelin‑A (ET_A) receptor, inhibiting endothelin‑1 induced vasoconstriction
Routes of Administration
Goals & Uses
- Model hypertension mechanismsResearchModerate
- Hypertension researchCardiovascularModerate
- Pulmonary arterial hypertension (PAH) researchCardiovascularModerate
- Heart failure hemodynamic researchCardiovascularModerate
- Raynaud's phenomenon / peripheral vascular diseaseVascularLow
- Study endothelin‑A receptor functionResearchHigh
- Renal vascular physiologyRenalLow
Contraindications
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Hypersensitivity to BQ-123 or peptide excipientsAllergic/ImmunologicHigh
- Severe hypotensionCardiovascularHigh
Adverse Effects
- Vasodilation / flushingCardiovascularCommon
- Injection site reactionsLocalUncommon
- HeadacheNeurologicUncommonPain in the head or upper neck
- HypotensionCardiovascularUnknownLow blood pressure
Drug Interactions
- Antihypertensive agentsModerate
- Endothelin-B (ETB) antagonistsModerate
- Phosphodiesterase-5 (PDE5) inhibitorsModerate
Population Constraints
- Pediatric populationsAgeRelative
- Patients with severe hepatic impairmentHepaticRelative
- Pregnant womenReproductiveAbsolute
Regulatory Status
- European UnionUnapprovedNot authorized for clinical use
- United StatesUnapprovedInvestigational reagent only
- United KingdomUnapprovedResearch chemical
Not approved for human therapeutic use; employed only in experimental and preclinical settings.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is BQ-123?
BQ‑123 is a cyclic hexapeptide that selectively blocks ET_A receptors and is widely used in pre‑clinical studies to explore endothelin‑mediated pathways.
What is BQ-123 used for?
BQ-123 is educationally associated with: Model hypertension mechanisms, Hypertension research, Pulmonary arterial hypertension (PAH) research, Heart failure hemodynamic research, Raynaud's phenomenon / peripheral vascular disease, Study endothelin‑A receptor function, Renal vascular physiology. Educational only — not medical advice.
How is BQ-123 administered?
Recorded routes of administration: Intracoronary, Intraperitoneal, Intravenous, Subcutaneous.
What are the potential side effects of BQ-123?
Reported adverse effects include: Vasodilation / flushing, Injection site reactions, Headache, Hypotension. This list is not exhaustive — consult a qualified clinician.
Who should avoid BQ-123?
Recorded contraindications: Pregnancy, Hypersensitivity to BQ-123 or peptide excipients, Severe hypotension. Consult a qualified clinician before use.